Ambisome Articles
Product News In 1996 Dominated By CNS
23 December 1996
Sequus Amphotec Launched In USA
16 December 1996
US Approval For Sequus' Amphotec
2 December 1996
Fujisawa USA Submits NDA For AmBisome
18 November 1996
Interim Financial Results From The USA
18 November 1996
Sequus Files To Trial SPI-77 For Tumors
4 November 1996
Liposome Company's Expanded Abelcet Approved In USA
4 November 1996
NeXstar's AmBisome; New Findings
14 October 1996
S-P Antifungals Promising
14 October 1996
Amphotericin B And Analogs In Prion Disease
30 September 1996
Amphotec In Bone Marrow Transplants
22 July 1996
Amphotec And Aspergillosis
24 June 1996
Progress At Sequus In 1995 Marked By Doxil Launch
17 June 1996
TLC Share Sale Probed
3 June 1996
AmBisome In India
20 May 1996
TLC Seeks New Uses For Abelcet
29 April 1996
First Sales Of Sequus' Doxil Reported
15 April 1996
Abelcet Of Use In Pediatric Candidiasis
15 April 1996
Abelcet Gains First-Line Indication
25 March 1996
Amphocil Cleared In Czech Republic
11 March 1996
The Liposome Company's Abelcet
11 March 1996
Amphocil Approved In Czech Republic
19 February 1996
Mixed Earnings But Strong Sales For US Companies
12 February 1996
Aronex' NystatinLF in Phase III
5 February 1996
NexStar'a Ambisome gets new indication approval
29 January 1996
Xoma Selects Lead Antifungal
22 January 1996
Sequus Amphotec news
18 December 1995
Liposome Company/ Laboratorios Esteve: Albelcet agreement
18 December 1995
Progress Towards Goals By US BioPharma Firms
4 December 1995
Sequus Gets First Approval For Doxil
27 November 1995
TLCGets US Go-Ahead For Abelcet
27 November 1995
Spain Approves TLC's Abelcet
20 November 1995
Liposome Company's Albecet gets new approval
6 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Aronex' NystatinLF: Phase I Results
25 September 1995
Results To June 30 See Losses For Smaller US Firms
21 August 1995
Itraconazole foe AIDS
19 June 1995
TLC Launches Abelcet In 1st Market, The UK
24 April 1995
Drug Therapy For Prion Diseases?
3 April 1995
First Approval For TLC's Amphotericin B
6 March 1995
Liposome Co Completes Ph II TLC C-53 ARDS Trials
30 January 1995
Liposome US Patent Invalid
9 January 1995
Liposome Technology's DOX-SL
19 December 1994
Pfizer's Diflucan Efficacy In Candidemia
21 November 1994
Amphocil Approved In Ireland
31 October 1994
ABLC Effective In Serious Fungal Disease
31 October 1994
UK Code Of Conduct Quarterly Review
17 October 1994
Zeneca Gets First Full Approval For Merrem
5 September 1994
EU APPLICATIONS FOR AMPHOCIL COMPLETE
13 June 1994
ZENECA LAUNCHES AMPHOCIL IN UK
16 May 1994
CORPORATE NEWSIN BRIEF
28 March 1994
PRODUCT SETBACK AT THE LIPOSOME CO
7 March 1994
SYNTEX EXPECTS PATENT EXPIRY EFFECTS
13 December 1993
SHAMAN PHARMA ON THE WARPATH
25 October 1993
FIRST APPROVAL FOR AMPHOCIL
6 September 1993
ZENECA IN EUROPEAN DEAL WITH LIPOSOME
23 August 1993
GROWING PROBLEM OF ANTIFUNGAL RESISTANCE
26 July 1993
AMBISOME REFORMULATIONS
21 June 1993
ALKERMES TRIALS
10 May 1993
LIPOSOSME VESTAR PATENT DISPUTE
12 April 1993
LIPOSOME STARTS PHASE III TRIAL
1 March 1993
VESTAR CHALLENGE TO LTI PATENT
8 February 1993
LIPOSOME FILES PLA IN UK
25 January 1993
AMBISOME LEADS VESTAR SUCCESS
5 October 1992
TLC SUES RIVAL VESTAR
6 July 1992
LTI'S DOXIL: EARLY PHASE I RESULTS
15 June 1992
TLC CHAIRMAN LOOKS BACK ON 1991
18 May 1992
DANISH COMPLAIN OVER GLAXO PRICING
23 March 1992
NONABSORBABLE ANTIBIOTICS
9 March 1992
VESTAR'S AMBISOME LAUNCHED IN THE UK
3 February 1992
NEW US PATENTS FOR TLC
27 January 1992
LIPOSOME CO'S R&D UPDATE AT HAMBRECHT CONF
27 January 1992
PFIZER'S DIFLUCAN & AIDS-ASSOCIATED CM
13 January 1992
EC PLENARY SESSION DECISIONS
6 January 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
